• About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • #5613 (no title)
Menu
  • About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • #5613 (no title)
Contact Us
  • About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • Contact Us
Menu
  • About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • Contact Us
Contact Us

The philosophy

Ikigai

/ˈɪkɪɡʌɪ/ /ˈiːkɪɡʌɪ/
Japanese concept that means “a purpose for being.”
Watch New Brand Video
Illustrated in the diagram below is an ideal framework to express our brand identity. Each of the 4 quadrants support the NattoPharma founders’ original passion for finding a natural solution for improved bone and heart health through science.

THe SYMBOL

Born out of the Ikigai core shape, where the two links represent:
  • You and NattoPharma
  • Science and Partnership
As the only K2 supplier who can provide you with human clinical studies to validate health claims for your MenaQ7® K2 products, we see the new symbol also resembling a compass, representing NattoPharma as your K2 guide.

the tagline

Simply states what we will experience together:
You will come for the science, but you will stay for the partnership.
We earn Customers’ trust because they know we created the category and continue to drive the science.
But it is the value we add to the Partnership – truly helping our Customers succeed — that makes the relationship so awesome.

what's staying the same

  • Our purpose-led commitment to provide you with increasingly better tools, knowledge, marketing, and product support, as if we were your own personal “back-office”.
  • The only company to provide crucial clinical evidence to support the health claims you can confidently make to improve consumers' health.
  • Supplying of the most comprehensive Vitamin K2 portfolio – both natural fermented and nature-identical synthesis in various dilutions and solubilities.
  • Personalized support paired with portfolio flexibility to bring your product ideas to life.
It’s satisfying to know that we not only were the first to bring to market this vital ingredient that fulfills our mission to improve health but also, we created the K2 category and the opportunity for hundreds of other businesses to thrive,”
– Frode Bohan, Founder

SCROLL the journey

NattoPharma Develops the Category and Brings Vitamin K2 to the Masses

2004
2006
2009
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021

K2 Origins and Discovery

1603-1867 – Edo period, Japan
Japanese first consume fermented soybeans, called “natto”.
1943 – Nobel Prize in Medicine
Shared by Henrik Dam (DK) for discovery of vitamin K and Edward Doisy (US) for discovery of its chemical structure.
1950s – “ACTIVATOR X”
Dr. Weston Price identifies fat-soluble vitamin missing in modern diets that is connected to bone and teeth degeneration.

Inspired by Natto’s Link to Bone Health

Founders knew natto was unlikely to be a popular way to get K2 to the world.

Determined to Bring K2 to Humans Globally
they knew they had to find a way to move from observational to clinical proof.

Aligned with Univ. Maastricht Discovers K2
mechanism, elucidating K2’s benefits for bone and cardiovascular health as we know it today.

NattoPharma ASA Founded with Mission
to bring K2 to the masses and provide clinical proof of its health benefits.

The First K2 Ingredient

MenaQ7 is first commercially available vitamin K2 as MK-7 dietary supplement ingredient.

MenaQ7 Bone Study in Healthy

prepubertal children publishes in the Br J Nutr.

MenaQ7 K Deficiency Study

in hemodialysis patients publishes in the Amer J Kid Dis.

MenaQ7 Dose-Finding Safety Study
publishes in the Brit J Nutr.

Breakthrough 3-Year MenaQ7 Bone

study publishes in Osteo Int’l

MenaQ7 Study Examining K2
status in children and adults publishes in Food & Function.

MenaQ7 Study Exploring K2
supplementation impact on OAC therapy publishes in Thromb and Haemo.

MenaQ7 Dose-Finding Study
in haemodialysis patients publishes in Nephr Dial Trans.

US Patent Application Expanded

for food products containing K2.

K2 & Omega-3 Canadian Patent
awarded to NattoPharma

Breakthrough MenaQ7 3-Year Cardio

study publishes in Thromb and Haemo

MenaQ7 PURE is Best New Ingredient
at Natural Products Expo West; granted Novel Food Approval from EFSA

Drug Master File completed

2.9M Euro Grant Awarded
to NattoPharma Research Network.

MenaQ7 is Non-GMO Verified


Awarded New Patent
allowing claims MK-7 reduces incidence of age-related hardening of arteries.

MenaQ7 Study Confirms
effective delivery via yogurt.

MenaQ7 Inflammation Study
publishes in J Med Food.

Horizon 2020 EU Research Grant

NattoPharma named partner.

4M Euro Research Grant
awarded to NattoPharma Research Network.

Norwegian Research Council Grant
awarded to NattoPharma.

MenaQ7 Natto MK-7; Full Spectrum K2
launches.

MenaQ7 1-Year Cardio Study

in men and women is complete.

K2 RDI program
spearheaded by NattoPharma.

K2 RDI Effort:

paper by NattoPharma research partner identifies need for K2 RDI.

K2 RDI effort:
new paper defines roles of Vitamins K1 and K2.

NattoPharma Advances Cardio Argument
with grant-funded paper.

UK Consumer Outreach Program
features MenaQ7 products; results in increased awareness.

Univ. Maastricht Research

partnership renewed.


MenaQ7 1-Year Cardio Study
in men and women publishes in Vasc Dis Thera.


K2 RDI effort:
paper by NattoPharma research partner identifies need for K2 RDI.


COVID-19 and Vitamin K
status connection first identified in preliminary research.

New US Office / Warehouse

opens to meet increased demand and
on-site personnel.


NattoPharma Acquired
by Compagnie Des Levures Lesaffre.

MEET THE TEAM

Management

The NattoPharma team is a carefully selected team with decades of experience serving and understanding the nutraceutical industry.

Kjetil Ramsøy

Chief Executive Officer
kjetil.ramsoy@nattopharma.com

Robert Schrama

Chief Financial Officer
robert.schrama@nattopharma.com

William Sommer

SVP R&D & Compliance
william.sommer@nattopharma.com

Laura Bakker

Supply Chain Manager
laura.bakker@nattopharma.com

Andrew Green

VP Global Marketing & Communications

andrew.green@nattopharma.com

Elise Kaiser

VP Sales, Americas
elise.kaiser@nattopharma.com

Rudi de Man

VP Sales, EMEA APAC
rudi.deman@nattopharma.com

Eric Anderson

SVP New Business Development
eric.anderson@nattopharma.com

board of directors

Frode Bohan
Chairman
Frode Bohan started his career within the industry in 1991 and founded the original NattoPharma Ltd (later NattoPharma ASA) in 2004, where he has been a significant shareholder from the incorporation. After two decades-long track record of founding and establishing prosperous companies, Mr. Bohan serves now as the Executive Chairman of NattoPharma. Mr. Bohan has studied marketing and computer science and based on the experience from building the MenaQ7 brand, he founded NoLabel and NutriCon, which are the world leading nutraceutical and pharmaceutical communications companies. Moreover, Mr. Bohan is a substantial Shareholder of Eqology ASA, and the chairman of the Board of directors at ImmunoPharma AS.
Sjur Thorsheim
Board Member
Sjur Thorsheim holds a law degree from the University of Oslo. For the last 20 years he has been a professional investor, investing in non-listed companies within industries such as aerospace, real estate, advertising, and security.
Annette Elmqvist
Board Member
Annette Elmqvist, Pharmacist from Uppsala University. Started her career at the Medical Product agency and over 20 years within former Pharmacia as Qualified person/Production manager, Director of Operation at SBL vaccine and CEO at Unitech Biopharma. Current position is VP Quality Assurance at Scandinavian Biopharma AB. The broad experience within pharmaceutical industry especially within quality and production processes give her the mission to support companies to develop new products.
Stefan Hallden
Board Member
Mr. Halldén is today working chairman of Life Science Sweden AB, a long-time shareholder in NattoPharma and a valuable contributor to the development of the company. The last year he also held the position as a member of the Election Committee. Halldén has a long track record from international finance.
Frode Bohan
Chairman

 

Sjur Thorsheim
Board Member
Annette Elmqvist
Board Member

 

Stefan Hallden
Board Member

 

Katarzyna Maresz
Board Member

 

Frode Bohan started his career within the industry in 1991 and founded the original NattoPharma Ltd (later NattoPharma ASA) in 2004, where he has been a significant shareholder from the incorporation. After two decades-long track record of founding and establishing prosperous companies, Mr. Bohan serves now as the Executive Chairman of NattoPharma. Mr. Bohan has studied marketing and computer science and based on the experience from building the MenaQ7 brand, he founded NoLabel and NutriCon, which are the world leading nutraceutical and pharmaceutical communications companies. Moreover, Mr. Bohan is a substantial Shareholder of Eqology ASA, and the chairman of the Board of directors at ImmunoPharma AS.

Sjur Thorsheim holds a law degree from the University of Oslo. For the last 20 years he has been a professional investor, investing in non-listed companies within industries such as aerospace, real estate, advertising, and security.

Annette Elmqvist, Pharmacist from Uppsala University. Started her career at the Medical Product agency and over 20 years within former Pharmacia as Qualified person/Production manager, Director of Operation at SBL vaccine and CEO at Unitech Biopharma. Current position is VP Quality Assurance at Scandinavian Biopharma AB. The broad experience within pharmaceutical industry especially within quality and production processes give her the mission to support companies to develop new products.

Mr. Halldén is today working chairman of Life Science Sweden AB, a long-time shareholder in NattoPharma and a valuable contributor to the development of the company. The last year he also held the position as a member of the Election Committee. Halldén has a long track record from international finance.

Katarzyna Maresz is a master’s graduate at the Jagiellonian University, Pharmacy Faculty (specialization: Medical Analytics, 1998). Holds a PhD in Biological Sciences at the Medical Faculty of the Jagiellonian University (2002). Held her practice at the Laboratory of Cellular and Molecular Immunology, Blood Research Institute, in Milwaukee, WI, USA (2003-2006). She is a post-doctoral fellow within the Marie-Curie Programme at the Department of Microbiology. Currently she is a scientific staff member at the Department of Biochemistry, Biophysics and Biotechnology at the Jagiellonian University as a part of a research project financed by the European Union.

Katarzyna Maresz
Board Member
Katarzyna Maresz is a master’s graduate at the Jagiellonian University, Pharmacy Faculty (specialization: Medical Analytics, 1998). Holds a PhD in Biological Sciences at the Medical Faculty of the Jagiellonian University (2002). Held her practice at the Laboratory of Cellular and Molecular Immunology, Blood Research Institute, in Milwaukee, WI, USA (2003-2006). She is a post-doctoral fellow within the Marie-Curie Programme at the Department of Microbiology. Currently she is a scientific staff member at the Department of Biochemistry, Biophysics and Biotechnology at the Jagiellonian University as a part of a research project financed by the European Union.

DRIVEN TO DISCOVER

Our Science

Our reputation as the unquestionable leader in Vitamin K2 Research and Development stems from our long-standing relationships with the most significant researchers. The result is 20 published human clinical trials (and more underway), which has cultivated our understanding of K2 as we know it today and serve as the foundation of the Vitamin K2 category itself.
Learn More

DRIVEN TO DISCOVER

Our Science

Our reputation as the unquestionable leader in Vitamin K2 Research and Development stems from our long-standing relationships with the most significant researchers. The result is 20 published human clinical trials (and more underway), which has cultivated our understanding of K2 as we know it today and serve as the foundation of the Vitamin K2 category itself.
Learn More

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor

NattoPharma
  • Mission & Purpose
  • K2 Timeline
  • Management Team
  • K2 Science
  • K2 in Numbers
  • Mission & Purpose
  • K2 Timeline
  • Management Team
  • K2 Science
  • K2 in Numbers
MenaQ7®️
  • Why MenaQ7®️
  • Quality Statement
  • Benefits
  • Partner Benefits
News & Events
  • News & Press
  • Event Calendar
Contact Us

Let's improve health!

How can we help?
  • Oslo, Norway (Main)
  • New Jersey, USA
  • Contact Us
© Copyright 2022 NattoPharma.
All rights reserved

We value your privacy

We access information on a device, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for personalised ads and content, ad and content measurement, and audience insights, as well as to develop and improve products.

With your permission we and our partners may use precise geolocation data and identification through device scanning. You may click to consent to our and our partners’ processing as described above. Alternatively you may click to refuse to consent or access more detailed information and change your preferences before consenting.

Please note that some processing of your personal data may not require your consent, but you have a right to object to such processing. Your preferences will apply to this website only. You can change your preferences at any time by returning to this site or visit our privacy policy.

Agree
Disagree